

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

HLF

RRID:CVCL_2947

Type: Cell Line

Proper Citation

RRID:CVCL_2947

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2947

Proper Citation: RRID:CVCL_2947

Description: Cell line HLF is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:52570](#), [PMID:1778766](#), [PMID:7874267](#), [PMID:8389256](#), [PMID:9290701](#), [PMID:10523694](#), [PMID:12029633](#), [PMID:15767549](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:31978347](#), [PMID:32899426](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HLF

Cross References: CLO:CLO_0009987, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:657, BioSample:SAMN10987769, cancercellines:CVCL_2947, Cell_Model_Passport:SIDM00065, CGH-DB:9076-4, Cosmic:945157, Cosmic:1187332, Cosmic:1518229, Cosmic:2023860, Cosmic:2162527, DepMap:ACH-000393, GEO:GSM887086, GEO:GSM888156, GEO:GSM936758, GEO:GSM1374538,

GEO:GSM1669885, GEO:GSM2551567, IARC_TP53:2009, JCRB:JCRB0405, LiGeA:CCLE_520, LIMORE:HLF, LINCS_HMS:50015, LINCS_LDP:LCL-1938, Pharmacodb:HLF_549_2019, Progenetix:CVCL_2947, Wikidata:Q54889850

ID: CVCL_2947

Record Creation Time: 20220427T220436+0000

Record Last Update: 20260920T003800+0000

Ratings and Alerts

No rating or validation information has been found for HLF.

No alerts have been found for HLF.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yamane M, et al. (2026) H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression. JHEP reports : innovation in hepatology, 8(5), 101786.

Rose F, et al. (2026) A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients. International journal of cancer, 159(7), 1829.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. Cells, 15(1).

Tsuchiya H, et al. (2026) High-Throughput Heterospheroid-Based Screening Identifies Drugs That Reprogram Tumor-Associated Macrophages. Journal of immunology research, 2026(1), e2889509.

Dzama-Karels M, et al. (2025) Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival. Cell reports, 44(12), 116619.

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer research, 85(4), 660.

Dzama-Karels M, et al. (2025) Menin-MLL1 complex cooperates with NF-Y to promote HCC survival. bioRxiv : the preprint server for biology.

Jin C, et al. (2024) The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage. *Nucleic acids research*, 52(6), 3011.

Jinesh GG, et al. (2024) C19MC drives nucleolar invasion of mitochondria and meiotic nuclear division in human cancers. *iScience*, 27(11), 111132.

Breitenecker K, et al. (2023) Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. *Frontiers in oncology*, 13, 1238883.

Wehling L, et al. (2022) Spatial modeling reveals nuclear phosphorylation and subcellular shuttling of YAP upon drug-induced liver injury. *eLife*, 11.

Song T, et al. (2021) DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation. *Cell reports*, 36(12), 109739.

Lendvai G, et al. (2020) The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines. *Pathology oncology research : POR*, 26(4), 2669.

Hayashi T, et al. (2017) Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma. *Cancer cell international*, 17, 94.